LinkedIn Profile

Access PIQUR Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:piqurtherapeutics 3257645 May 31st, 2019 12:00AM PIQUR Therapeutics AG 891 24.00 Open Pharmaceuticals May 30th, 2019 11:30PM May 30th, 2019 11:30PM PIQUR Therapeutics is a Swiss clinical-stage pharmaceutical company, incorporated in August 2011 as a spin-off of the University of Basel, focused on the discovery and development of innovative anti-cancer drugs based on the inhibition of lipid kinase (PI3K) and mTOR. PIQUR’s pipeline originates from one of the most promising research areas in oncology, as both PI3K and mTOR are clinically validated drug targets. The company holds a worldwide exclusive license on the intellectual property rights for development and commercialization of Bimiralisib and related series of analogues. For more information, please visit www.piqur.com Open Oncology, Small Molecules, Hematology, Drug Development Open Hochbergerstrasse 60C Basel CH CH-4057 Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 17th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 16th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 15th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 14th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 13th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 12th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 11th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 10th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services
private:piqurtherapeutics 3257645 Feb 9th, 2018 12:00AM PIQUR Therapeutics AG 535 29.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications. Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.